Subcutaneous Spesolimab Reduces GPP Flares: Phase 2 Study Subcutaneous Spesolimab Reduces GPP Flares: Phase 2 Study

For generalized pustular psoriasis, treatment with the subcutaneously administered IL-36 receptor antagonist resulted in a significant reduction in flares compared with placebo.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news